干细胞疗法真的可以治疗多发性硬化症吗?

2016-08-15 佚名 生物谷

近日,据每日邮报(Daily Mail)报道,在进行造血干细胞(Haematopoietic Stem Cells)治疗后数天后,多发性硬化症(MS,Multiple sclerosis)患者Eric Thompson从轮椅上站了起来,并且能够正常走路了。不能够接受来自英国国民健康保险制度(National Health Service,NHS)提供的积极性疗法,最终患者Thompson和

近日,据每日邮报(Daily Mail)报道,在进行造血干细胞(Haematopoietic Stem Cells)治疗后数天后,多发性硬化症(MS,Multiple sclerosis)患者Eric Thompson从轮椅上站了起来,并且能够正常走路了。不能够接受来自英国国民健康保险制度(National Health Service,NHS)提供的积极性疗法,最终患者Thompson和其家人筹集了4万英镑并且在墨西哥开始了这项疗法。

Thompson所接受的这种疗法名为自身造血干细胞移植疗法(AHSCT),进行这种疗法首先就是从患者骨髓或者血液中抽取干细胞,当患者进行进行集中性的化疗削弱自身免疫系统的功能后,从患者机体抽取的干细胞被再次注入到患者体内,这一操作就是为了重新启动患者机体的免疫系统,而集中性的高剂量化疗方法的使用及移植过程往往也是疗法进行过程中比较艰难的过程。

据英国癌症研究中心数据显示,供体的干细胞移植物往往被用作治疗多种类型癌症,包括白血病、淋巴瘤和骨髓瘤,然而如今推荐自身造血干细胞移植疗法作为治疗多发性硬化症的疗法或许为时过早。

尽管目前NHS不能提供此疗法,但英国多发性硬化症协会报道了许多研究都利用自身造血干细胞移植疗法来治疗多发性硬化症,而且研究者们表示这种疗法具有极大的前景,同时经这种疗法治疗的患者,疾病的复发率降低了,患者恢复也比较稳定,甚至某些患者的残疾症状也被逆转了。然而多发性硬化症协会强调,这或许并不适用于每一名患者,而且这种疗法或许具有一定的“攻击性”且会引发明显的风险。

临床试验

目前一系列利用自身造血干细胞移植来治疗多发性硬化症的疗法都正在进行,包括2015年3月进行的ASTIMS试验,这项试验对21名复发缓解型多发性硬化症患者(患者个体有不同的疾病症状)以及进展型多发性硬化症患者(患者残疾并不因疾病的复发)进行研究;相比较利用药物米托蒽醌治疗的患者而言,接受自身造血干细胞移植疗法的患者疾病的复发率名下下降了。

米托蒽醌是一种典型的化学疗法,其可被用作疾病修饰疗法来减少疾病复发的多发性硬化症患者的数量,然而研究者表示,某些接受自身造血干细胞移植疗法的患者往往会经历严重的副作用,比如血小板减少症、嗜中性白血球减少症、感染以及肝脏毒性表现,而且其中两名患者还遭受了威胁生命的一些状况,包括出现败血症、严重感染、骨髓干细胞移植成活率较低以及治疗完全失败等情况。

英国是进行随机临床试验MIST多个国家中的一个(多个国家包括英国、美国、瑞典和巴西),多个接受自身造血干细胞移植疗法的患者都表现出了积极性的可喜结果,患者表示他们机体的多发性硬化症症状得到了明显改善和逆转,而且MRI扫描结果也显示患者机体中并未活动性疾病的证据,所有的临床试验结果都将于2017年进行公布,而且很多患者也都期待积极性数据的早日公布。英国的研究中心位于皇家海莱姆医院(Royal Hallamshire Hospital),部分临床试验患者也已于2016年1月出现在了英国广播公司BBC的全景栏目(Panorama Programme)中。

目前正在加拿大进行的一项自身造血干细胞移植临床试验结果提出了多发性硬化症患者疾病复发率和疾病活动性的明显变化,其中大约70%的患者都表现出了疾病进展完全停止的迹象。但正在进行试验的患者中有一名患者因肝衰竭而出现了死亡,这或许是疗法的一种副作用所引发的;研究者强调说,必须爱活动进展性的多发性硬化症患者中考虑这些疗法相关的风险。

患者Eric Thompson的故事为自身造血干细胞移植疗法在多发性硬化症患者中的应用起到了极大的推动作用,但同时我们不应当忽视该疗法带来的风险以及成本花费;多发性硬化症协会生物医学研究所的主任Sorrel Bickley认为,这项积极性的疗法往往会伴随一定风险的存在,其需要经过专家们的再次确认,同时也应当在认证中心进行实施。我们并不清楚自身造血干细胞移植疗法带来的长期效应,这就强调了后期临床试验的重要性。

参考资料:

【1】I can walk again after years in a wheelchair': Father with MS stands up within DAYS of having stem cell therapy in Mexico

【2】Stem cell transplants

【3】Autologous Haematopoietic Stem Cell Transplantation (AHSCT)

【4】Relapsing Remitting (RRMS)

【5】Secondary Progressive MS (SPMS)

【6】Mitoxantrone

【7】Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

【8】MS breakthrough: Replacing diseased immune system halts progression and allows repair

【9】Can stem cell therapy really treat multiple sclerosis?

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2017-05-22 jml2009
  2. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 doctorJiangchao

    继续学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 doctorJiangchao

    继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1889687, encodeId=76c7188968e07, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Mon May 22 05:09:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982926, encodeId=ed621982926ab, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Nov 23 21:09:00 CST 2016, time=2016-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314454, encodeId=2154131445452, content=<a href='/topic/show?id=4c6348e80a9' target=_blank style='color:#2F92EE;'>#干细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48780, encryptionId=4c6348e80a9, topicName=干细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Wed Aug 17 01:09:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98953, encodeId=032498953fb, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98954, encodeId=0d9e9895484, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98955, encodeId=42239895510, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Aug 15 20:23:00 CST 2016, time=2016-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=98894, encodeId=36ea988949a, content=好好学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Mon Aug 15 19:11:00 CST 2016, time=2016-08-15, status=1, ipAttribution=)]
    2016-08-15 忠诚向上

    好好学习一下

    0

相关资讯

Nat Commun:干细胞疗法治疗糖尿病日渐成熟 科学家已经实现利用病人组织获得β细胞

(上图表明病人组织来源β细胞与正常人组织来源β细胞的分子标记无差异)   最近,来自华盛顿大学医学院和哈佛大学的研究人员利用1型糖尿病病人组织形成的诱导多能干细胞分化得到具有胰岛素分泌功能的β细胞,为治疗糖尿病找到一个新的潜在方法。1型糖尿病病人自身无法合成胰岛素,因此需要常规注射胰岛素帮助控制血糖。这项最新发现表明糖尿病个体化治疗已见曙光。   相关研究结果发表在

太深?Teva放弃一个III期心衰干细胞疗法的开发权利

Teva近日宣布将MPC-150-IM的开发权利全部归还给澳大利亚Mesoblast公司。 Teve决定放弃开发MPC-150-IM,但是Mesoblast表示将继续推进这个项目,并且会寻找新的合作伙伴来推进MPC-150-IM的上市以及全球销售工作。Mesoblast表示MPC-150-IM的后续研发费用大约要1亿美元,公司有足够的现金来完成相关研发工作。 Mesoblast称,独立的数

PLoS Comput Biol:计算机模拟间充质干细胞疗法 将心脏病治疗风险降至很低

最近科学家们使用数学计算模型模拟了人类间充质干细胞到达心脏损伤部位的过程,发现只用一个特定亚群的干细胞就能最大限度地减少间充质干细胞疗法带来的相关风险。相关研究结果发表在国际学术期刊Plos Computational Biology上,该研究代表了心肌损伤修复和再生策略的新发展,能够提高干细胞疗法在心脏病患者中的应用安全性。心肌梗死——也即心脏病发作——在美国平均每43秒就会发生。这一情况大大激

Neurology:临床试验证明干细胞疗法治疗“渐冻症”的安全性 解救“渐冻人”有望落实行动

日前一项对肌萎缩侧索硬化症(ALS)病人进行的2期临床试验表明将人类干细胞移植到病人的脊髓中已经具备安全性,有望扩大临床试验样本量进一步验证干细胞疗法治疗ALS的效果。该研究发表在国际学术期刊Neurology上。 ALS是脑和脊髓运动神经元退化导致的一种神经紊乱疾病,该病患者会逐渐失去肌肉控制能力,包括呼吸和吞咽,最终导致死亡。目前仍然没有有效方法可以阻止这种疾病。 参与该研究的

Stroke:干细胞疗法可有效治疗中风

  (图片摘自www.sciencealert.com)   患有中风的患者在经过向大脑中注射干细胞治疗,能够明显地提高其讲话能力、身体强度以及行动力。其中一些患者甚至能够重新行走。   这一临床试验的成功意味着我们低估了大脑自愈的能力,也许有一天这种疗法能够使大脑重新恢复功能。   "一位71岁的老年女性在治疗开始前仅仅能够活动左手大拇指

Nature:千呼万唤始出来 中国颁布干细胞管理规范

干细胞疗法是本世纪最有前景的疗法之一。研究人员通过利用干细胞能够分化为多种细胞类型的能力来设计疗法,可以用于治疗癌症、糖尿病以及神经退行性疾病等多个领域的疾病。在这一领域,中国也不落人后。许多科学家都在该领域做出了出色的工作。据统计,2014年中国科学家发表的关于干细胞方面的论文数已经超过了日本,仅次于美国。(相关阅读:中国在干细胞领域发表论文数超过日本)然而,在干细胞疗法方面,中国和世界上许多其